Evidence map›Paper›PMID 41091380›Full record

ArticleJournal of neuro-oncology2025

Systemic immune-inflammation index as a prognostic biomarker to predict overall survival after primary stereotactic radiosurgery for brain metastases.

Sukwoo Hong, Hirokazu Takami, Motoyuki Umekawa, Yuki Shinya, Hirotaka Hasegawa, Mariko Kawashima, Yosuke Kitagawa, Masashi Nomura, Shunsaku Takayanagi, Shota Tanaka and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sukwoo HongDepartment of Neurosurgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Hirokazu TakamiDepartment of Neurosurgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. takamih-nsu@h.u-tokyo.ac.jp.
Motoyuki UmekawaDepartment of Neurosurgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Yuki ShinyaDepartment of Neurosurgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Hirotaka HasegawaDepartment of Neurosurgery, Saitama Medical Center, Saitama, Japan.
Mariko KawashimaGamma Knife Center, NTT Medical Center Tokyo, Tokyo, Japan.
Yosuke KitagawaDepartment of Neurosurgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Masashi NomuraDepartment of Neurosurgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Shunsaku TakayanagiDepartment of Neuro-Oncology, International Medical Center, Saitama Medical University, Saitama, Japan.
Shota TanakaDepartment of Neurological Surgery, Okayama Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Nobuhito SaitoDepartment of Neurosurgery, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the usefulness of the systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI) in predicting local tumor control (LC) duration and overall survival (OS) in patients with brain metastases treated with primary stereotactic radiosurgery (SRS).

methodsAll consecutive patients who underwent fractionated SRS between April 2018 and December 2022 were retrospectively analyzed. Statistical analyses included Cox regression and Kaplan-Meier curves.

resultsA total of 132 metastases in 65 patients were analyzed. The median SII was 909 (IQR 524–1696), and the median SIRI was 1.6 (IQR 0.7–3.1). The median LC duration was 10 months, with 66.7% of lesions under control, 13.6% progressed, and 19.7% had unknown status due to insufficient imaging. The median OS was 11 months; 83% of patients had died by the last follow-up. SII and SIRI were not associated with LC duration in univariable Cox regression analysis. However, higher SII (p = 0.05) was significantly associated with worse OS in multivariable Cox regression analysis, along with male sex (p < 0.01) and gastrointestinal cancer origin (p = 0.02). These findings were also supported by Kaplan-Meier curves with log-rank tests. The optimal SII cutoff for predicting OS was 2600 (concordance index 0.72; hazard ratio 2.65). SIRI was associated with OS in univariate analysis (p = 0.03), but not multivariable analysis.

conclusionThis study suggests that higher SII was associated with worse OS and that it can be useful markers to predict OS, but not LC duration.

Indexed as

Brain NeoplasmsInflammationRadiosurgeryAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateIndexInflammationRadiosurgerySIISIRI

Identifiers

PMID41091380
PMCPMC12528272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.